drugset / Trial / NCT02112903

Study Comparing the Gastro-intestinal Tolerability and Absorption Profile of Vortioxetine After Administration of Modified-release Formulations and Immediate-release Formulation in Healthy Women

NCT02112903

Phase 1 Completed 40 enrolled H. Lundbeck A/S
RandomizedCrossoverDouble-blindTreatment

Summary

The purpose of this study is to evaluate the gastro-intestinal tolerability (nausea, vomiting, diarrhoea, abdominal discomfort, and abdominal pain) of vortioxetine following single oral doses of three modified-release (MR) capsules with differently coated multiple particles compared to one immediate-release (IR) tablet.

Timeline

Start
2014-04
Primary completion
2014-09
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Vortioxetine Unknown 20 mg Oral

Indications

No indication recorded.